



## Clinical Policy: Cosyntropin (Cortrosyn)

Reference Number: LA.PHAR.203

Effective Date: 09.15.22

Last Review Date: ~~03.05.25~~~~05-06-24~~

Line of Business: Medicaid

[Coding Implications](#)

[Revision Log](#)

See [Important Reminder](#) at the end of this policy for important regulatory and legal information.

**\*\*Please note: This policy is for medical benefit\*\***

### Description

Cosyntropin (Cortrosyn<sup>®</sup>) is a synthetic subunit of adrenocorticotrophic hormone (ACTH).

### FDA Approved Indication(s)

Cortrosyn is indicated in combination with other diagnostic tests, for use as a diagnostic agent in the screening of ~~patients presumed to have~~ adrenocortical insufficiency in adult and pediatric patients.

### Policy/Criteria

*Provider must submit documentation (such as office chart notes, lab results or other clinical information) supporting that member has met all approval criteria.*

It is the policy of Louisiana Healthcare Connections that Cortrosyn is **medically necessary** when the following criteria are met:

## I. Initial Approval Criteria

### A. Presumed Adrenocortical Insufficiency (must meet all):

1. Prescribed for diagnostic testing of adrenocortical insufficiency;
2. If Cortrosyn is requested, member must use generic cosyntropin, unless contraindicated or clinically significant adverse effects are experienced;
3. Dose does not exceed a single dose of one of the following (a or b):
  - a. If age < 2 years: 0.125 mg ~~per dose~~ (1 vial);
  - b. If age  $\geq$  2 years: 0.~~75~~25 mg ~~per dose~~ (3 vials ~~(1 vial)~~).

**Approval duration: 1 dose**

### B. Other diagnoses/indications (must meet 1 or 2):

1. If this drug has recently (within the last 6 months) undergone a label change (e.g., newly approved indication, age expansion, new dosing regimen) that is not yet reflected in this policy, refer to LA.PMN.255
2. If the requested use (e.g., diagnosis, age, dosing regimen) is NOT specifically listed under section III (Diagnoses/Indications for which coverage is NOT authorized) AND criterion 1 above does not apply, refer to the off-label use policy LA.PMN.53

## II. Continued Therapy

### A. Presumed Adrenocortical Insufficiency

Formatted: No underline

**CLINICAL POLICY**  
Cosyntropin



1. Re-authorization is not permitted. Members must meet the initial approval criteria.

**Approval duration: Not applicable**

**B. Other diagnoses/indications** (must meet 1 or 2):

1. If this drug has recently (within the last 6 months) undergone a label change (e.g., newly approved indication, age expansion, new dosing regimen) that is not yet reflected in this policy, refer to LA.PMN.255
2. If the requested use (e.g., diagnosis, age, dosing regimen) is NOT specifically listed under section III (Diagnoses/Indications for which coverage is NOT authorized) AND criterion 1 above does not apply, refer to the off-label use policy: LA.PMN.53

**III. Diagnoses/Indications for which coverage is NOT authorized:**

- A. Non-FDA approved indications, which are not addressed in this policy, unless there is sufficient documentation of efficacy and safety according to the off label use policy LA.PMN.53

**IV. Appendices/General Information**

*Appendix A: Abbreviation/Acronym Key*

ACTH: adrenocorticotrophic hormone

FDA: Food and Drug Administration

*Appendix B: Therapeutic Alternatives*

Not applicable

*Appendix C: Contraindications/Boxed Warnings*

- Contraindication(s): hypersensitivity to ~~Cosyntropin injection, synthetic ACTH, cosyntropin~~ or to any of the excipients of ~~Cortrosyn~~.
- Boxed warning(s): none reported

**V. Dosage and Administration**

Indication	Dosing Regimen	Maximum Dose
Diagnostic testing of adrenal insufficiency	<del>0.25-0.75 mg</del> Single dose administered by IV or IM; <del>in pediatric injection</del>  Adults: 0.25 mg Pediatric patients < 2 years: 0.125 mg <del>will often suffice</del> Pediatric patients 2 to 17 years: 0.25 mg	<del>0.75 mg/dose</del> See dosing regimen

Formatted: No underline

**VI. Product Availability**

Vial for injection: 0.25 mg

**VII. References**

1. ~~Cortrosyn~~ Prescribing Information. Rancho Cucamonga, CA. Amphastar Pharmaceuticals, Inc.; December ~~2024~~2023. Available at

Formatted: Spanish (Spain)

**CLINICAL POLICY**  
Cosyntropin



- [https://www.accessdata.fda.gov/drugsatfda\\_docs/label/2021/016750Orig1s032lbl/2023/016750s033lbl.pdf](https://www.accessdata.fda.gov/drugsatfda_docs/label/2021/016750Orig1s032lbl/2023/016750s033lbl.pdf). Accessed October 19, 2023, 2024.
2. Cosyntropin Drug Monograph. Clinical Pharmacology. Elsevier; 2022. Available at: <https://www.clinicalkey.com/pharmacology/>. Accessed October 19, 2023.
  3. Bornstein, S, Allolio B, Arlt, Wiebke, et al. Diagnosis and Treatment of Primary Adrenal Insufficiency: An Endocrine Society Clinical Practice Guideline. The Journal of Clinical Endocrinology and Metabolism. Feb 2016; 101(2): 364-389.

Formatted: German (Germany)

**Coding Implications**

Codes referenced in this clinical policy are for informational purposes only. Inclusion or exclusion of any codes does not guarantee coverage. Providers should reference the most up-to-date sources of professional coding guidance prior to the submission of claims for reimbursement of covered services.

HCPCS Codes	Description
J0834	Injection, cosyntropin, 0.25 mg

Reviews, Revisions, and Approvals	Date	LDH Approval Date
Converted corporate to local policy.	09.22	09.15.22
Template changes applied to other diagnoses/indications. Modified dosing limits for age 2 or less to 0.125 mg per prescribing information; removed inactive HCPCS code J0833; references reviewed and updated. Added verbiage this policy is for medical benefit only.	06.02.23	10.05.23
Annual review: no significant changes; references reviewed and updated.	05.06.24	<u>07.29.24</u>
<u>Annual review; updated maximum dosing in those age 2 years and older to 0.25 mg as a single-dose per updated prescribing information; references reviewed and updated</u>	<u>03.05.25</u>	

**Important Reminder**

This clinical policy has been developed by appropriately experienced and licensed health care professionals based on a review and consideration of currently available generally accepted standards of medical practice; peer-reviewed medical literature; government agency/program approval status; evidence-based guidelines and positions of leading national health professional organizations; views of physicians practicing in relevant clinical areas affected by this clinical policy; and other available clinical information. LHCC makes no representations and accepts no liability with respect to the content of any external information used or relied upon in developing this clinical policy. This clinical policy is consistent with standards of medical practice current at the time that this clinical policy was approved.

The purpose of this clinical policy is to provide a guide to medical necessity, which is a component of the guidelines used to assist in making coverage decisions and administering benefits. It does not constitute a contract or guarantee regarding payment or results. Coverage

## CLINICAL POLICY

### Cosyntropin



decisions and the administration of benefits are subject to all terms, conditions, exclusions and limitations of the coverage documents (e.g., evidence of coverage, certificate of coverage, policy, contract of insurance, etc.), as well as to state and federal requirements and applicable LHCC administrative policies and procedures.

This clinical policy is effective as of the date determined by LHCC. The date of posting may not be the effective date of this clinical policy. This clinical policy may be subject to applicable legal and regulatory requirements relating to provider notification. If there is a discrepancy between the effective date of this clinical policy and any applicable legal or regulatory requirement, the requirements of law and regulation shall govern. LHCC retains the right to change, amend or withdraw this clinical policy, and additional clinical policies may be developed and adopted as needed, at any time.

This clinical policy does not constitute medical advice, medical treatment or medical care. It is not intended to dictate to providers how to practice medicine. Providers are expected to exercise professional medical judgment in providing the most appropriate care, and are solely responsible for the medical advice and treatment of members. This clinical policy is not intended to recommend treatment for members. Members should consult with their treating physician in connection with diagnosis and treatment decisions.

Providers referred to in this clinical policy are independent contractors who exercise independent judgment and over whom LHCC has no control or right of control. Providers are not agents or employees of LHCC.

This clinical policy is the property of LHCC. Unauthorized copying, use, and distribution of this clinical policy or any information contained herein are strictly prohibited. Providers, members, and their representatives are bound to the terms and conditions expressed herein through the terms of their contracts. Where no such contract exists, providers, members and their representatives agree to be bound by such terms and conditions by providing services to members and/or submitting claims for payment for such services.

©2025 Louisiana Healthcare Connections. All rights reserved. All materials are exclusively owned by Louisiana Healthcare Connections and are protected by United States copyright law and international copyright law. No part of this publication may be reproduced, copied, modified, distributed, displayed, stored in a retrieval system, transmitted in any form or by any means, or otherwise published without the prior written permission of Louisiana Healthcare Connections. You may not alter or remove any trademark, copyright or other notice contained herein. Louisiana Healthcare Connections is a registered trademark exclusively owned by Louisiana Healthcare Connections.